Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
I'm LongbridgeAI, I can summarize articles.
Boris Peaker of JonesTrading has reiterated a Buy rating on ELVN-001, maintaining a $45 price target due to strong clinical data and strategic positioning. The drug shows promising molecular response rates and tolerability in late-line CML patients. Peaker highlights ELVN-001's unique mechanism and efficacy compared to competitors, alongside the company's solid cash position. Guggenheim also initiated coverage with a Buy rating and a $80 price target. Peaker has a 20.3% average return and a 45.78% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments